ALK Fusion Probe21

$30.00
Street Address NO666,Gaoxin Boulevard ,Optics Valley Biolake,Building B6
City Wuhan
ZIP/Postal Code 430075
State Hubei
Country China
3 Views

Product Name:ALK Fusion Probe

Product Description:ALK Gene Fusion Detection ProbeProduct Advantages:?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.3.Reproducibility: Different laboratories test results are highly reproducibleProduct Description :Lung cancer, Anaplastic large cell lymphomaAbout ALKThe ALK gene encodes a transmembrane receptor tyrosine kinase (RTK). The ALK-NPM1 fusion protein was originally found in anaplastic large cell lymphoma and in other tumors including neuroblastoma and non-small cell lung cancer. The gene was found to be mutated, amplified, or rearranged, with chromosome rearrangements being the most common, resulting in ALK fusion with other genes including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3) , ALK / NPM1 (chromosome 5), ALK / SQSTM1 (chromosome 5), ALK / KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (X chromosome).?Probe DescriptionALK gene break apart probe uses orange labeled dye ALK gene (3 \’ End) 2p23.2 region, and a green dye ALK gene (5\’ End) to mark 2p23.1-p23.2 region. ALK gene break apart probe can detect all ALK gene rearrangement, avoiding missed diagnosis caused by a single fusion gene (such as EML4-ALK). The 2013 edition of China anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer diagnosis expert consensus pointed out that adenocarcinoma, for age (60 years old), nonsmoking, EGFR, KRAS, HER2 or P53 in patients without NSCLC gene mutations, ALK gene positive rate is high as 30%~ 42%. Pathological studies suggest that the positive rate in signet-ring cell-containing mucinous or solid adenocarcinoma is higher than other types of lung adenocarcinoma. In 2013, CFDA approved XALKORI (Crizotinib) for targeted therapy of advanced ALK-positive non-small cell lung cancer, and the necessary condition for XALKORI (Crizotinib) drug treatment was FISH for the detection of ALK-positive non-small cell lung cancer. ALK-positive gene fusion patients are sensitive to XALKORI (Crizotinib) treatment.??Size SpecificationsReferences :l? Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.l? Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.l? Von Laffert M, et al. (2013) Lung Cancer 81: 200-6.

Price:30.00

Product Website: http://www.health-carebiotech.com/molecular-diagnostic-probe/fluorescence-in-situ-hybridization-probes/alk-fusion-probe.html

Company Description: Wuhan Healthcare Biotechnology co.,Ltd

Address: HubeiHubeiWuhanDonghuNO666,Gaoxin Boulevard ,Optics Valley Biolake,Building B6

Descption: HealthCare Biotech is a molecular diagnostics manufacturer of Fluorescence in-situ hybridization (FISH) probes for cancer and hematology , Real-Time PCR kits and Automation for use in medical research and diagnostics.

Registered Capital: 860

EmployeeNum: 100

Wuhan Healthcare Biotechnology co.,Ltd

Contact: Nyobe Lambert

Telphone: 86-027-65022930

Fax: 86-027-87850869

Email: [email protected]

Company Website: http://www.health-carebiotech.com

Leave comment for this ad